PAIP2
gene geneOn this page
Also known as PAIP2A
Summary
PAIP2 (poly(A) binding protein interacting protein 2, HGNC:17970) is a protein-coding gene on chromosome 5q31.2, encoding Polyadenylate-binding protein-interacting protein 2 (Q9BPZ3). Acts as a repressor in the regulation of translation initiation of poly(A)-containing mRNAs.
Enables translation repressor activity. Involved in negative regulation of translational initiation. Located in cytoplasm.
Source: NCBI Gene 51247 — RefSeq curated summary.
At a glance
- GWAS associations: 6
- Clinical variants (ClinVar): 18 total
- MANE Select transcript:
NM_016480
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:17970 |
| Approved symbol | PAIP2 |
| Name | poly(A) binding protein interacting protein 2 |
| Location | 5q31.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | PAIP2A |
| Ensembl gene | ENSG00000120727 |
| Ensembl biotype | protein_coding |
| OMIM | 605604 |
| Entrez | 51247 |
Gene structure
Transcript identifiers
Ensembl transcripts: 23 — 20 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined
ENST00000265192, ENST00000394795, ENST00000507415, ENST00000507755, ENST00000510080, ENST00000510409, ENST00000511381, ENST00000511706, ENST00000881921, ENST00000881922, ENST00000881923, ENST00000917509, ENST00000917510, ENST00000917511, ENST00000917512, ENST00000917513, ENST00000917514, ENST00000917515, ENST00000917516, ENST00000954475, ENST00000954476, ENST00000954477, ENST00000954478
RefSeq mRNA: 2 — MANE Select: NM_016480
NM_001033112, NM_016480
CCDS: CCDS4211
Canonical transcript exons
ENST00000265192 — 4 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001425481 | 139341854 | 139341980 |
| ENSE00001898705 | 139368733 | 139369717 |
| ENSE00003513430 | 139364564 | 139364743 |
| ENSE00003561860 | 139363759 | 139363922 |
Expression profiles
Bgee: expression breadth ubiquitous, 268 present calls, max score 99.78.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 83.9466 / max 910.9452, expressed in 1822 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 58824 | 83.8235 | 1822 |
| 58827 | 0.0722 | 20 |
| 58826 | 0.0318 | 5 |
| 58825 | 0.0191 | 5 |
Top tissues by expression
268 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| cardiac muscle of right atrium | UBERON:0003379 | 99.78 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 99.77 | gold quality |
| cerebellar vermis | UBERON:0004720 | 99.44 | gold quality |
| pons | UBERON:0000988 | 99.36 | gold quality |
| myocardium | UBERON:0002349 | 99.35 | gold quality |
| kidney epithelium | UBERON:0004819 | 99.26 | gold quality |
| thymus | UBERON:0002370 | 99.15 | gold quality |
| deltoid | UBERON:0001476 | 99.10 | gold quality |
| tibialis anterior | UBERON:0001385 | 99.08 | gold quality |
| cartilage tissue | UBERON:0002418 | 99.05 | gold quality |
| postcentral gyrus | UBERON:0002581 | 99.05 | gold quality |
| upper arm skin | UBERON:0004263 | 99.02 | gold quality |
| embryo | UBERON:0000922 | 99.01 | gold quality |
| ganglionic eminence | UBERON:0004023 | 99.01 | gold quality |
| quadriceps femoris | UBERON:0001377 | 98.99 | gold quality |
| superior vestibular nucleus | UBERON:0007227 | 98.95 | gold quality |
| parotid gland | UBERON:0001831 | 98.94 | gold quality |
| vastus lateralis | UBERON:0001379 | 98.93 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 98.89 | gold quality |
| parietal lobe | UBERON:0001872 | 98.88 | gold quality |
| substantia nigra pars compacta | UBERON:0001965 | 98.87 | gold quality |
| heart right ventricle | UBERON:0002080 | 98.82 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 98.77 | gold quality |
| substantia nigra | UBERON:0002038 | 98.72 | gold quality |
| monocyte | CL:0000576 | 98.71 | gold quality |
| prefrontal cortex | UBERON:0000451 | 98.71 | gold quality |
| ventricular zone | UBERON:0003053 | 98.71 | gold quality |
| midbrain | UBERON:0001891 | 98.70 | gold quality |
| hypothalamus | UBERON:0001898 | 98.69 | gold quality |
| leukocyte | CL:0000738 | 98.65 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ENAD-17 | no | 632.15 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
99 targeting PAIP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-200B-3P | 100.00 | 73.31 | 2693 |
| HSA-MIR-200C-3P | 100.00 | 73.35 | 2685 |
| HSA-MIR-429 | 100.00 | 73.44 | 2698 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-29A-3P | 100.00 | 73.11 | 1835 |
| HSA-MIR-29B-3P | 100.00 | 73.18 | 1833 |
| HSA-MIR-29C-3P | 100.00 | 73.15 | 1833 |
| HSA-MIR-371B-5P | 99.99 | 75.34 | 4759 |
| HSA-MIR-27A-3P | 99.98 | 72.13 | 2955 |
| HSA-MIR-27B-3P | 99.98 | 72.13 | 2955 |
| HSA-MIR-9985 | 99.98 | 72.11 | 2939 |
| HSA-MIR-4775 | 99.98 | 75.00 | 6394 |
| HSA-MIR-373-5P | 99.98 | 75.36 | 4753 |
| HSA-MIR-616-5P | 99.98 | 75.58 | 4775 |
| HSA-MIR-5688 | 99.96 | 73.23 | 4504 |
| HSA-MIR-495-3P | 99.96 | 72.81 | 4197 |
| HSA-MIR-590-3P | 99.96 | 74.34 | 6478 |
| HSA-MIR-3658 | 99.96 | 73.87 | 4379 |
| HSA-MIR-128-3P | 99.95 | 71.17 | 2484 |
| HSA-MIR-216A-3P | 99.95 | 71.19 | 2505 |
| HSA-MIR-144-3P | 99.94 | 73.98 | 2698 |
| HSA-MIR-539-5P | 99.93 | 70.30 | 2855 |
| HSA-MIR-218-5P | 99.93 | 72.22 | 2103 |
| HSA-MIR-338-5P | 99.92 | 72.34 | 2951 |
| HSA-MIR-1305 | 99.91 | 71.43 | 3443 |
| HSA-MIR-7-1-3P | 99.91 | 71.53 | 4384 |
| HSA-MIR-7-2-3P | 99.91 | 71.40 | 4394 |
| HSA-MIR-498-3P | 99.91 | 71.27 | 1114 |
| HSA-MIR-4302 | 99.89 | 67.94 | 1187 |
| HSA-MIR-3681-3P | 99.88 | 70.46 | 2254 |
Literature-anchored findings (GeneRIF, showing 5)
- Role of PAIP2 in modulation of GLUT5 mRNA stability. (PMID:12820898)
- PAIP2 is a crucial regulator of VEGF mRNA and has a role in regulating angiogenesis (PMID:15175342)
- The turnover of Paip2 in the cell is mediated by EDD and is regulated by PABP. (PMID:16601676)
- Paip2 is a host antiviral restriction factor antagonized by PABP accumulation in HCMV-infected cells (PMID:23964095)
- These results indicated that PAIP1 and PAIP2 participate in translation termination and are important regulators of readthrough at the premature termination codon. (PMID:30992367)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Paip2 | ENSMUSG00000037058 |
| rattus_norvegicus | Paip2 | ENSRNOG00000019934 |
| drosophila_melanogaster | Paip2 | FBGN0038100 |
Paralogs (1): PAIP2B (ENSG00000124374)
Protein
Protein identifiers
Polyadenylate-binding protein-interacting protein 2 — Q9BPZ3 (reviewed: Q9BPZ3)
All UniProt accessions (3): D6R9Y1, D6RA77, Q9BPZ3
UniProt curated annotations — full annotation on UniProt →
Function. Acts as a repressor in the regulation of translation initiation of poly(A)-containing mRNAs. Its inhibitory activity on translation is mediated via its action on PABPC1. Displaces the interaction of PABPC1 with poly(A) RNA and competes with PAIP1 for binding to PABPC1. Its association with PABPC1 results in disruption of the cytoplasmic poly(A) RNP structure organization.
Subunit / interactions. Interacts with the second and third RRM domains and C-terminus regions of PABPC1 in a 2:1 stoichiometry.
Subcellular location. Cytoplasm.
Tissue specificity. Expressed at highest level in testis, but also abundant in brain, cervix, lung, ovary, placenta, adipose tissue, thymus and thyroid.
Post-translational modifications. Ubiquitinated, leading to its degradation by the proteasome.
Domain organisation. Only the PABPC1-interacting motif-1 (PAM1) interferes with the binding of PABPC1 to poly(A) RNA and translation initiation.
Similarity. Belongs to the PAIP2 family.
RefSeq proteins (2): NP_001028284, NP_057564* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR009818 | PAM2_motif | Conserved_site |
| IPR040396 | PAIP2-like | Family |
Pfam: PF07145
UniProt features (7 total): region of interest 3, sequence conflict 2, chain 1, compositionally biased region 1
Structure
Experimental structures (PDB)
3 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 3KUS | X-RAY DIFFRACTION | 1.4 |
| 3KUT | X-RAY DIFFRACTION | 1.5 |
| 1JGN | SOLUTION NMR |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9BPZ3-F1 | 72.02 | 0.26 |
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-9820841 | M-decay: degradation of maternal mRNAs by maternally stored factors |
MSigDB gene sets: 205 (showing top):
GOBP_MEMORY, TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_COGNITION, GOBP_BEHAVIOR, GOBP_TRANSLATIONAL_INITIATION, AP2_Q3, GOBP_MALE_GAMETE_GENERATION, GOBP_NEGATIVE_REGULATION_OF_TRANSLATION, GOBP_CELL_CELL_SIGNALING, GOBP_NEGATIVE_REGULATION_OF_TRANSLATIONAL_INITIATION, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, GOMF_TRANSLATION_REGULATOR_ACTIVITY, GOBP_REGULATION_OF_SYNAPTIC_PLASTICITY, OCT1_03
GO Biological Process (7): translation (GO:0006412), spermatogenesis (GO:0007283), memory (GO:0007613), negative regulation of translation (GO:0017148), negative regulation of translational initiation (GO:0045947), regulation of long-term synaptic potentiation (GO:1900271), regulation of translation (GO:0006417)
GO Molecular Function (4): mRNA regulatory element binding translation repressor activity (GO:0000900), mRNA binding (GO:0003729), translation repressor activity (GO:0030371), protein binding (GO:0005515)
GO Cellular Component (1): cytoplasm (GO:0005737)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| Maternal to zygotic transition (MZT) | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| translational initiation | 2 |
| translation | 2 |
| negative regulation of translation | 2 |
| peptidyltransferase activity | 1 |
| translational elongation | 1 |
| translational termination | 1 |
| macromolecule biosynthetic process | 1 |
| protein metabolic process | 1 |
| protein biosynthetic process | 1 |
| developmental process involved in reproduction | 1 |
| male gamete generation | 1 |
| learning or memory | 1 |
| regulation of translation | 1 |
| negative regulation of gene expression | 1 |
| negative regulation of protein metabolic process | 1 |
| regulation of translational initiation | 1 |
| regulation of synaptic plasticity | 1 |
| long-term synaptic potentiation | 1 |
| post-transcriptional regulation of gene expression | 1 |
| regulation of protein metabolic process | 1 |
| mRNA binding | 1 |
| translation repressor activity | 1 |
| RNA binding | 1 |
| translation regulator activity | 1 |
| binding | 1 |
| intracellular anatomical structure | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
842 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| PAIP2 | PABPC1 | P11940 | 977 |
| PAIP2 | PAIP1 | Q9H074 | 940 |
| PAIP2 | EIF4G1 | Q04637 | 783 |
| PAIP2 | ELAVL1 | Q15717 | 772 |
| PAIP2 | EIF3J | O75822 | 768 |
| PAIP2 | ANKRD52 | Q8NB46 | 671 |
| PAIP2 | RRM2 | P31350 | 560 |
| PAIP2 | PABPC4 | Q13310 | 559 |
| PAIP2 | PABPC1L | Q4VXU2 | 554 |
| PAIP2 | PABPC5 | Q96DU9 | 541 |
| PAIP2 | PABPC3 | Q9H361 | 521 |
| PAIP2 | HNRNPL | P14866 | 466 |
| PAIP2 | PABPC4L | P0CB38 | 460 |
| PAIP2 | EIF4E | P06730 | 454 |
| PAIP2 | PABPC1L2A | Q5JQF8 | 452 |
IntAct
60 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| PAIP2 | PABPC1 | psi-mi:“MI:0915”(physical association) | 0.860 |
| PABPC1 | PAIP2 | psi-mi:“MI:0407”(direct interaction) | 0.860 |
| PABPC1 | PAIP2 | psi-mi:“MI:0915”(physical association) | 0.860 |
| PAIP2 | PABPC1 | psi-mi:“MI:0407”(direct interaction) | 0.860 |
| N | PABPC1 | psi-mi:“MI:0915”(physical association) | 0.700 |
| PAIP2 | UBR5 | psi-mi:“MI:0915”(physical association) | 0.680 |
| PAIP2 | UBR5 | psi-mi:“MI:0407”(direct interaction) | 0.680 |
| UBR5 | PAIP2 | psi-mi:“MI:0407”(direct interaction) | 0.680 |
| UBR5 | PAIP2 | psi-mi:“MI:0220”(ubiquitination reaction) | 0.680 |
| PABPC5 | PAIP2 | psi-mi:“MI:0915”(physical association) | 0.670 |
| DNALI1 | PAIP2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| KLF11 | PAIP2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| PAIP2 | NUP58 | psi-mi:“MI:0915”(physical association) | 0.560 |
| PABPC1 | P/V/C | psi-mi:“MI:0915”(physical association) | 0.520 |
| PAIP2 | NDN | psi-mi:“MI:0915”(physical association) | 0.470 |
| PABPC1 | P/V/C | psi-mi:“MI:0915”(physical association) | 0.400 |
BioGRID (94): PAIP2 (Affinity Capture-RNA), PAIP2 (Affinity Capture-MS), PAIP2 (Affinity Capture-MS), PAIP2 (Affinity Capture-MS), PAIP2 (Affinity Capture-MS), PAIP2 (Reconstituted Complex), PAIP2 (Reconstituted Complex), PAIP2 (Affinity Capture-MS), PAIP2 (Affinity Capture-MS), PAIP2 (Affinity Capture-MS), PAIP2 (Affinity Capture-RNA), PAIP2 (Affinity Capture-MS), PAIP2 (Affinity Capture-MS), PABPC5 (Two-hybrid), PAIP2 (Proximity Label-MS)
ESM2 similar proteins: A1YEW9, A2D4U8, A2D5N1, A2D671, A2T6K9, A8MQL1, B8AE37, F4HY56, G3V9A7, O23116, O60238, P48785, P79149, Q0DKP4, Q15170, Q15361, Q15390, Q1PEB4, Q2KIJ9, Q3T013, Q3ULM0, Q3ZBJ9, Q5H9J7, Q5PPP3, Q5PR69, Q5RFN3, Q5XVC4, Q67XL4, Q6K678, Q7XRV0, Q86X53, Q8GYL9, Q8GZ92, Q8RY18, Q91W45, Q921P9, Q94F39, Q96GX8, Q99MB2, Q9AV50
Diamond homologs: Q3ZC67, Q5R596, Q5ZJS6, Q6AXZ0, Q91W45, Q9BPZ3, Q9D6V8, Q9ULR5
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| UBR5 | “down-regulates quantity by destabilization” | PAIP2 | polyubiquitination |
Disease & clinical
Clinical variants and AI predictions
ClinVar
18 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 15 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
781 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 5:139363757:A:G | acceptor_gain | 1.0000 |
| 5:139363905:G:GT | donor_gain | 1.0000 |
| 5:139363918:GACAA:G | donor_gain | 1.0000 |
| 5:139363920:CAAG:C | donor_loss | 1.0000 |
| 5:139363923:G:GG | donor_gain | 1.0000 |
| 5:139363924:T:G | donor_gain | 1.0000 |
| 5:139364732:G:GT | donor_gain | 1.0000 |
| 5:139341945:GA:G | donor_gain | 0.9900 |
| 5:139341979:GG:G | donor_gain | 0.9900 |
| 5:139341980:GG:G | donor_gain | 0.9900 |
| 5:139341980:GGT:G | donor_loss | 0.9900 |
| 5:139341981:GT:G | donor_loss | 0.9900 |
| 5:139341982:T:G | donor_loss | 0.9900 |
| 5:139342054:GGGCC:G | donor_gain | 0.9900 |
| 5:139363756:AAG:A | acceptor_gain | 0.9900 |
| 5:139363758:G:A | acceptor_gain | 0.9900 |
| 5:139363758:G:GC | acceptor_loss | 0.9900 |
| 5:139363758:G:GG | acceptor_gain | 0.9900 |
| 5:139363758:GGTTA:G | acceptor_gain | 0.9900 |
| 5:139363919:A:G | donor_gain | 0.9900 |
| 5:139363919:ACAA:A | donor_gain | 0.9900 |
| 5:139363921:AA:A | donor_gain | 0.9900 |
| 5:139363925:TAGTT:T | donor_loss | 0.9900 |
| 5:139364556:A:AG | acceptor_gain | 0.9900 |
| 5:139364557:A:G | acceptor_gain | 0.9900 |
| 5:139364560:CTA:C | acceptor_loss | 0.9900 |
| 5:139364561:TA:T | acceptor_loss | 0.9900 |
| 5:139364562:A:AG | acceptor_gain | 0.9900 |
| 5:139364563:G:GG | acceptor_gain | 0.9900 |
| 5:139364563:G:T | acceptor_loss | 0.9900 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000013410 (5:139363668 A>C), RS1000185574 (5:139345869 C>T), RS1000212599 (5:139360361 C>G), RS1000217972 (5:139345616 C>T), RS1000383563 (5:139340283 A>C,T), RS1000409692 (5:139340579 C>A,G), RS1000501105 (5:139364153 A>C), RS1000522816 (5:139347238 C>T), RS1000607282 (5:139357080 C>G), RS1000709632 (5:139353196 T>C), RS1000728620 (5:139352931 C>T), RS1000772632 (5:139351607 A>G), RS1000813100 (5:139359151 T>A), RS1000889839 (5:139344656 A>G), RS1001007084 (5:139346964 C>G)
Disease associations
OMIM: gene MIM:605604 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
6 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST005951_151 | Body mass index | 6.000000e-07 |
| GCST010725_68 | Malaria | 4.000000e-07 |
| GCST010725_7 | Malaria | 2.000000e-06 |
| GCST90002385_347 | High light scatter reticulocyte count | 2.000000e-11 |
| GCST90002386_41 | High light scatter reticulocyte percentage of red cells | 9.000000e-11 |
| GCST90002387_310 | Immature fraction of reticulocytes | 1.000000e-09 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004340 | body mass index |
| EFO:0007986 | reticulocyte count |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
32 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | decreases expression, increases expression, affects cotreatment | 3 |
| aristolochic acid I | decreases expression | 1 |
| bisphenol F | increases expression | 1 |
| dicrotophos | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| sodium arsenite | increases expression | 1 |
| cupric oxide | increases expression | 1 |
| ICG 001 | increases expression | 1 |
| abrine | decreases expression | 1 |
| jinfukang | decreases expression | 1 |
| bisphenol AF | increases expression | 1 |
| Air Pollutants | affects expression, increases abundance | 1 |
| Ethanol | affects cotreatment, decreases expression, increases abundance | 1 |
| Arsenic | affects methylation | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Bile Acids and Salts | increases expression | 1 |
| Dexamethasone | affects cotreatment, increases expression | 1 |
| Estradiol | decreases expression | 1 |
| Ethyl Methanesulfonate | increases expression | 1 |
| Fructose | affects binding, increases reaction | 1 |
| Gasoline | decreases expression, increases abundance, affects cotreatment | 1 |
| Glucose | affects binding, increases reaction | 1 |
| Indomethacin | affects cotreatment, increases expression | 1 |
| Methyl Methanesulfonate | increases expression | 1 |
| Ozone | affects expression, increases abundance | 1 |
| Polycyclic Aromatic Hydrocarbons | affects cotreatment, decreases expression, increases abundance | 1 |
| Potassium Dichromate | increases expression | 1 |
| Tobacco Smoke Pollution | increases expression | 1 |
| Tretinoin | decreases expression | 1 |
| Valproic Acid | decreases expression | 1 |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B3D9 | Abcam HEK293T PAIP2 KO | Transformed cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.